This brand name is authorized in South Africa
The drug RADD contains one active pharmaceutical ingredient (API):
1
Methylphenidate
UNII 4B3SC438HI - METHYLPHENIDATE HYDROCHLORIDE
|
Methylphenidate HCl is a mild central nervous system (CNS) stimulant. The mode of therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known. Methylphenidate is thought to block the reuptake of noradrenaline and dopamine into the presynaptic neurone and increase the release of these monoamines into the extraneuronal space. |
Below package inserts are available for further reading:
Title | Information Source | Document Type | |
---|---|---|---|
RADD Prolonged-release tablet | Health Products Regulatory Authority (ZA) | MPI, Generic |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
N06BA04 | Methylphenidate | N Nervous system → N06 Psychoanaleptics → N06B Psychostimulants, agents used for ADHD and nootropics → N06BA Centrally acting sympathomimetics |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: ZA | Health Products Regulatory Authority | Identifier(s): 51/1.2/0289, 51/1.2/0290, 51/1.2/0291, 51/1.2/0292 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.